摘要
目的探讨雷贝拉唑三联疗法治疗Hp相关性消化性溃疡的临床疗效。方法雷贝拉唑三联疗法治疗经胃镜检查确诊的Hp相关性消化性溃疡68例。分为实验组：雷贝拉唑（波利特）10mg，1次／d×14d，羟氨苄青霉素1．0g，2次／d×7d，克拉霉素0．5g，2次／d×7d；对照组：奥美拉唑（奥美）20mg，1．7次／d×14d，羟氨苄青霉素、克拉霉素均同实验组。全部疗程结束后4周，复查胃镜及Hp，观察溃疡愈合和Hp根除以及不良反应情况。结果实验组和对照组两组得愈合率及总有效率相似（P〉0．05）。且Hp根除率实验组为93．18％（31／34），对照组为76．47％（26／34），两组间经x0检验差异有统计学意义（X2=7．58，P〈0．05）。10例出现不良反应。结论雷贝拉唑三联疗法具有溃疡愈合迅速、症状消失快、Hp根除率高与奥美拉唑组相比较，雷贝拉唑组在症状缓解率及溃疡愈合方面更具优势。
Objective To explore the efficacy of rabeprazole triple therapy regimens in the treatment of Helicobacter pylori - related ulcer. Methods 68 cases with documented peptic ulcer and Hp infection by endoscopic examination and rapid urease test were randomized to receive rabeprazole or omeprazole - based triple therapy regimenss. The experimental group ： Rabeprazole（Pollitt） 10 mg,1 times/d × 14 d, amoxycillin 1.0 g, 2 times/d ×7 d, clarithromycin 0.5 g, 2 timcs/d x7 d; and the Contralgroup：Omeprazale （Mather） 20 rag, 1 time/d × 14 d,amoxycillin, clarithromycin were the same test group. All four weeks after the end of treatment, review of endoscopy and Hp, ulcer healing and Hp observation, as well as adverse reactions to eradicate the situation. Results The healing rate and the two groups was the total effective rate is similar between the test group and control group （ P 〉 0.05 ）. Hp eradication rate and the test group was 93.18% （ 31/34 ）, the control group was 76.47% （26/34）, and there were statistically significant differences （X2 = 7.58, P 〈 0.05 ） by X2 test between the two groups. Conclusion Compared with omeprazole - based triple therapy regimens, rabeprazole - based triple therapy regimens was better in the ulcer healing rate,symptomatic relief and Hp eradication rate.
出处
《中国医学创新》
CAS
2009年第20期42-43,共2页
Medical Innovation of China
